Therapeutic Effects of Gentiopicroside on Hyperandrogenism in Polycystic Ovary Syndrome via Rho/Rho-Associated Protein Kinase Signaling

摘要

The therapeutic efficacy of using gentiopicroside (GPS) in rats suffering from polycystic ovary syndrome (PCOS) by targeting the Rho/Rock signaling pathway was investigated. Forty Sprague-Dawley (SD) rats were randomly divided into a control group (n = 10) and a model preparation group (n = 30). The PCOS model rats were replicated using insulin (INS) combined with human chorionic gonadotropin-1 (HCG) method. The PCOS model rats were divided into model, high dose, and low dose groups (Single intravenous, GPS-H = 29.6 mg/kg, GPS-L = 7.4 mg/kg, respectively). The control group and model group were administered with the same volume of saline for 15 days. The expression of RhoA and pRhoA were evaluated by radio-immunoassay (RIA); the mRNA and protein expression levels of RhoA, pRhoA, P450scc, P450c17, and P450c20 were evaluated by RTPCR and western blot. The results showed that the expression levels of androstenedione (ASD) and 17-hydroxyprogesterone (17-OHP) were significantly higher in the model group than those in the control group (P < 0.05). Higher expressions of the RhoA, pRhoA, P450scc, P450c17, and P450c20 were induced in the PCOS model rats. Treatment with high and low doses of GPS resulted in the suppression of expressions of RhoA, pRhoA, P450scc, P450c17, and P450c20. These alterations provided a novel idea and method for exploring the interventional treatment of hyperandrogenism during PCOS by GPS.